Cargando…
Novel specific anti‐ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis
Suppressing tumors through anti‐angiogenesis has been established as an effective clinical treatment strategy. Bevacizumab, a monoclonal antibody, is commonly used in various indications. However, two major challenges limit the long‐term efficacy of bevacizumab: drug resistance and side effects. Bev...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637069/ https://www.ncbi.nlm.nih.gov/pubmed/37715566 http://dx.doi.org/10.1111/cas.15939 |